Ulisse Biomed Past Earnings Performance

Past criteria checks 0/6

Ulisse Biomed's earnings have been declining at an average annual rate of -72.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 40.1% per year.

Key information

-72.1%

Earnings growth rate

-38.2%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate-40.1%
Return on equity-28.2%
Net Margin-1,655.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

Jun 24
A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Feb 17
We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Ulisse Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BIT:UBM Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-720
31 Mar 240-610
31 Dec 230-510
30 Sep 230-310
30 Jun 230-210
31 Mar 230-100
31 Dec 220-100
30 Sep 220-100
30 Jun 220-100
31 Mar 220-100
31 Dec 210-100
30 Sep 210000
30 Jun 211000
31 Mar 211000
31 Dec 201000
31 Dec 190-110
31 Dec 180-210

Quality Earnings: UBM is currently unprofitable.

Growing Profit Margin: UBM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: UBM is unprofitable, and losses have increased over the past 5 years at a rate of 72.1% per year.

Accelerating Growth: Unable to compare UBM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: UBM has a negative Return on Equity (-28.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies